Car-Nk Cell

Neoplasm

The Second Hospital of Shandong UniversityCell therapyEarly Phase 1Active

C

39/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 24/ 100
Competitive Position: 95/ 100

Competitive context

889 Active assets in the Neoplasm cohort.

Asset / Sponsor	Phase	Rating
Panitumumab Astellas Pharma Inc	Phase 2	BBB
Granulocyte Colony-Stimulating Factor Lenograstim Sanofi	Phase 4	BB
Dexmedetomidine Medical College of Wisconsin	Phase 4	BB
Lidocaine Medical College of Wisconsin	Phase 4	BB
Relatlimab Bristol-Myers Squibb	Phase 2	BB

View all 50 →

Same molecule, other indications

Car-Nk Cell is also rated in:

Sjogren syndromeActive

CCC

Indicative · Phase 1/2

48 / 100

lymphomaActive

CC

Indicative · Phase 1/2

41 / 100

malignant pancreatic neoplasmActive

C

Indicative · Early Phase 1

39 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.